Eden News

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, will hold its AGM today at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED.

At the meeting Eden's Chairman, Tom Lupton, will make the following statement:

Since our last AGM, the Company has seen the first commercial sales of 3AEY in Italy, Spain and Greece; received registration of 3AEY in France, as well as other countries within the southern EU zone; signed an exclusive distribution agreement with Eastman Chemical for our nematicide product; and expanded its team through the appointment of experienced sector experts.

We have also today announced the signing of a number of important commercial agreements with Sipcam SpA who, at the same time, have made a strategic investment in Eden. This, in itself, is an important event which serves as a platform upon which we will be able to maximise the value of Eden, its products and technologies.

All of this, I hope, goes to show the significant progress that has been made over the last twelve months.

And yet, the next twelve months is set to be even better for Eden with first commercial sales of 3AEY in France in 2017; product registrations progressing in several regions, including the USA; distribution agreements to be signed covering multiple territories for 3AEY and other products; the launch of Bayer Animal Health's pet products; the launch of TerpeneTech's head-lice product; and research and development work being undertaken which will help to strengthen the Company's portfolio of products.

The Company is well-positioned to grow; by building market acceptance, share and reach of its products through strong partners, such as Sipcam, Eastman Chemical and Bayer Animal Health; by funding product and technology development through the resources that it now has available to it; by developing its own branding, including Sustaineä which will become increasingly well-known and sought after in the sectors in which Eden's technologies and products are commercialised.

The market for natural and naturally-derived products and technologies such as ours continues to grow at a rapid rate and we are pleased to be in a position to take full advantage of this.

Over the last year, Eden has started selling product on a commercial scale, which has moved us from being solely in a development phase to the commercialisation stage. We are now well positioned to build on this and all the development work that we have invested in to date. There is still much to do and more value to be derived and our expanded team will be concentrating its efforts on delivering this over the next twelve months.

Company presentation

After the conclusion of the formal business of the AGM, Eden's Chief Executive Officer, will provide a short presentation to investors with an overview of Company progress and strategy. No new material information will be disclosed in the presentation and it will be available on the Company website later today.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus and Albania.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Investment by strategic commercial partner and institutional placing

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough biocontrol products and natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that, further to the announcement earlier today, it has raised c.£2.4 million, before expenses, through a subscription (the "Subscription") for 20,494,330 new ordinary shares of 1p each in the Company ("Ordinary Shares") (the "Subscription Shares") and an institutional placing (the "Placing") of 1,915,888 new Ordinary Shares (the "Placing Shares") both at a price of 10.7 pence each.

Sipcam SpA ("Sipcam"), Eden's commercialisation partner in a growing list of countries, subscribed for the Subscription Shares which represent c.9.9 per cent. of the enlarged share capital.

The Company has also received a non-binding indication from an existing institutional investor for £300,000 of Ordinary Shares at the Placing Price (the "Additional VCT Placing"). The Additional VCT Placing is anticipated completing (subject to contract and relevant regulation) once the Company receives clearance from HMRC that the Company's business will qualify for the relevant tax reliefs in connection with the Additional VCT Placing. The Company will submit an application for clearance to HMRC shortly and it is anticipated by the Company that such clearance will be granted, should it be granted, within 2 - 3 months. Even if such clearance is granted, there can be no certainty that the Additional VCT Placing will occur. The Company will make further announcements as is appropriate.

Sean Smith, Chief Executive of Eden, said: "Eden and Sipcam have worked closely together and we have been pleased with the progress that Sipcam has made and the commercial traction that it achieved through the development and commercialisation of 3logyâ.

"Following the completion of a number of commercial agreements, as we announced earlier today, we believe that the investment by Sipcam aligns both parties' interests and will allow us to build on the momentum that the partnership has generated to date.

"In addition to the support provided by existing institutional investors, we are delighted to have Sipcam as a shareholder of Eden and believe that this investment, made by a significant and well respected leader in the agrochemicals industry, further validates Eden's technologies and products and will help us to achieve greater success and stature."

Nadia Gagliardini, President of Sipcam, said: "Since we started our collaboration with Eden we have believed that their technology has excellent potential and that the fit between Sipcam and Eden's expertise is highly complimentary. Sipcam is well recognised for its technical expertise and marketing capabilities, with a strong presence in key agricultural markets, while Eden's technology has proven to be very effective and to hold tremendous potential. The technology Eden has developed, along with the strength of Eden's management team, convinced Sipcam's Board to invest in the future of Eden, becoming a shareholder, with a long term perspective whilst contributing its expertise in the technical, marketing and industrial areas."

The Subscription Shares and the Placing Shares will rank pari passu in all respects with the Company's existing Ordinary Shares and will represent c.10.8% of the Company's enlarged issued share capital. Application has been made for the Subscription Shares and the Placing Shares to be admitted to AIM and it is expected that admission will take place on 5 July 2017 ("Admission").

Under the terms of its subscription for the Subscription Shares, Sipcam has been granted the right to appoint a director to the board of the Company for as long as it retains a minimum interest of seven and a half (7.5) per cent. of the issued share capital of the Company. The Parties have also signed a lock-in agreement which prevents Sipcam from selling its Placing Shares for a period of three years.

Following Admission, the Company's total issued and voting share capital will comprise 207,064,337 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, securities of the Company.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy and France.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

Sipcam was founded in 1946 in Milan, by Dr. Emilio Gagliardini and Prof. Baldo Ciocca, as a company specialized in manufacturing and marketing mainly agrochemicals in Italy, expanding then its presence in key agricultural markets, leveraging on products sourced by its sister company Oxon and thanks to collaboration with Japanese R&D Companies lasting since 1970.

The SIPCAM OXON group is made up of two separate legal entities (Sipcam and Oxon), which refer to one property and to one management, working independently but acting in synergy sharing mission and vision.

Sipcam Oxon is committed to maintain its independence by integration of entrepreneurship and management skills.

The industrial presence consists of one chemical synthesis plant in Italy, three formulation plants in Italy, Spain and Brazil, one seed processing and treatment plant in Italy and two synthesis and formulation plants operated by Chinese Joint Ventures.

For more information about Sipcam, please visit http://www.sipcam-oxon.com/public/

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough biocontrol products and natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that it has signed multiple new commercial and development agreements with its partner, Sipcam SpA ("Sipcam"), representing a significant expansion of the Company's existing relationship with them.

In addition to expanding the commercialisation "footprint" for 3AEY to include Australia, the companies are formalising their relationship as collaborators, and Eden is granting Sipcam the right to exclusively distribute Eden products in a range of new countries, including some of the largest markets for agrochemicals in the world. As part of Sipcam's overall commitment to the relationship with Eden (in addition to the Subscription (defined below)), in connection with the signed agreements, financial terms have been agreed which include an upfront cash payment to Eden of €0.6m and potential further future fees which are dependent upon which rights, if any, Sipcam decides to take.

The Company also announces that it proposing to raise in aggregate c.£2.4m (before expenses) through a subscription of up to 20,494,330 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") (the "Subscription Shares") and an institutional placing of up to 1,915,888 new Ordinary Shares (the "Placing Shares") (the "Placing") both at a price of 10.7 pence per new Ordinary Share. Sipcam is proposing to make a strategic investment of c.£2.2m in the Company and to enter into a subscription agreement to subscribe for the Subscription Shares (the "Subscription").

Commercial and Development Agreements with Sipcam

The agreements with Sipcam are summarised as follows:

• Collaboration and Evaluation & Option Agreements
  • Provides Sipcam with the first right to negotiate for the distribution rights for new plant protection products that Eden develops in countries where Sipcam has an affiliate, subject to certain ongoing commitments and evaluations.
  • Grants Eden access to Sipcam-owned technologies and R & D facilities.
  • Grants Sipcam the right to evaluate a number of Sipcam-Oxon Group's active substances encapsulated using Eden's Sustaineä microencapsulation technology. This includes combinations with Eden's own active ingredients.
  • Provides a framework agreement for subsequent licence and/or supply agreements under the collaboration.
     
• Distribution Agreements
  • Eden has agreed to appoint Sipcam as Eden's exclusive distributor in Italy, Spain and Australia for 3AEY.
  • 3AEY is Eden's first product that targets botrytis on grapes and a range of additional high value fruits and vegetables. It is sold as 3logy® in Italy and Araw® in Spain.
  • The existing licence agreements with Sipcam (covering Italy and Spain) will be terminated and replaced with the new distribution agreements reflecting the evolution of Eden's business model (from licensing to product sales) and providing Eden with the potential for both additional [future] revenue and improved profits.

Proposed Subscription and Placing

The Company is proposing to raise c.£2.4m (before expenses) through the Subscription and the Placing. The net proceeds of the Subscription and Placing would be used to:

• Register existing and new products and increase the global reach of existing Eden products
• Commence new R&D trials in both plant protection products and personal care applications
• Pursue commercialisation of animal health products outside of the United States
• Expand business and brand development activities

Sipcam is proposing to enter into a subscription agreement to subscribe for the Subscription Shares. Under the terms of their proposed subscription, Sipcam would enter into a lock-in agreement which would prevent Sipcam from selling its Subscription Shares for a period of three years. Sipcam would be granted the right to appoint a director to the board of the Company for as long as it retains a minimum interest of seven and a half (7.5) per cent. of the issued share capital of the Company.

The price for the Subscription Shares and the Placing Shares of 10.7 pence reflects the average share price over 60 business days up to 21 June 2017.

Assuming the full amount were issued, the Subscription Shares and the Placing Shares would represent in aggregate approximately 12.1% of the Company's current issued share capital.

Sean Smith, Chief Executive of Eden, said: "We are pleased to increase the breadth and depth of the commercial and collaborative development arrangements that we have with Sipcam. They have proven to be an excellent partner, and will be able to help us commercialise our products and technologies in certain key parts of the world at a much faster pace.

"The move from a licensing relationship to a distribution model in Italy and Spain is in line with management's announced strategy and will allow Eden to generate greater returns for the Company and its shareholders which will, in turn, enable us to build the business at an increased pace. In the short term, we will also be expanding this relationship to include Australia, the world's fifth largest producer of wine. Subject to further commercial and technical evaluations, Sipcam shall also have the right to commercialise 3AEY in additional key countries, subject to existing agreements and evaluations that are already underway.

"Sipcam is a well-established sales, marketing and distribution partner, as well as a formulator, to many of the leaders in the agrochemical industry and, as such, we are confident that they will continue to be excellent partners in this expanded relationship.

"The significant resource and knowledge that Sipcam has at its disposal, as well as the substantial investment they are making in the commercialisation of Eden's products and technology, will also serve us well in developing and, ultimately, distributing Eden's products and technologies in countries in which Sipcam has a presence and will also allow Eden to leverage those capabilities in countries where they do not."

Giovanni Affaba, Chief Executive Officer of Sipcam-Oxon Group, said: "We have had significant experience with Eden's products in Italy and Spain beginning in 2016 and resulting in the first product commercialisation in 2016. We recognized immediately the efficacy of the products on key targets and also the innovative technology Eden has developed. The potential of a joint effort focussed on developing new solutions and exploiting new markets became evident when Sipcam-Oxon and Eden put together their know-how and capabilities. The broad collaboration we have agreed upon is a cornerstone for developing and commercialising new and innovative products in the market in the next years."

This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR"). In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this Announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy and France.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

Sipcam was founded in 1946 in Milan, by Dr. Emilio Gagliardini and Prof. Baldo Ciocca, as a company specialized in manufacturing and marketing mainly agrochemicals in Italy, expanding then its presence in key agricultural markets, leveraging on products sourced by its sister company Oxon and thanks to collaboration with Japanese R&D Companies lasting since 1970.

The SIPCAM OXON group is made up of two separate legal entities (Sipcam and Oxon), which refer to one property and to one management, working independently but acting in synergy sharing mission and vision.

Sipcam Oxon is committed to maintain its independence by integration of entrepreneurship and management skills.

The industrial presence consists of one chemical synthesis plant in Italy, three formulation plants in Italy, Spain and Brazil, one seed processing and treatment plant in Italy and two synthesis and formulation plants operated by Chinese Joint Ventures.

For more information about Sipcam, please visit http://www.sipcam-oxon.com/public/

IMPORTANT NOTICE

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States, Canada, Australia, Japan, the Republic of South Africa or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction (the "Restricted Jurisdictions"). This announcement does not constitute or form part of any offer to sell, or any solicitation of an offer to buy, securities in the United States. The Placing Shares have not been and will not be registered under the Securities Act or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States absent registration except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. No public offering of the Placing Shares is being made in the United States. The Placing Shares are being offered and sold outside the United States in offshore transactions, as defined in, and in compliance with, Regulation S under the Securities Act. Persons receiving this announcement (including custodians, nominees and trustees) must not forward, distribute, mail or otherwise transmit it in or into the United States or use the United States mails, directly or indirectly, in connection with the Placing. This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Placing Shares in any jurisdiction including, without limitation, the Restricted Jurisdictions or any other jurisdiction in which such offer or solicitation is or may be unlawful. This announcement and the information contained in it is not for publication or distribution, directly or indirectly, to persons in a Restricted Jurisdiction unless permitted pursuant to an exemption under the relevant local law or regulation in any such jurisdiction.

No action has been taken by the Company, Shore Capital and Corporate Limited, Shore Capital Stockbrokers Limited (together with Shore Capital and Corporate Limited, "Shore Capital") or any of their respective directors, officers, partners, agents, employees or affiliates that would permit an offer of the Placing Shares or possession or distribution of this announcement or any other publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required. Persons receiving this announcement are required to inform themselves about and to observe any such restrictions.

This announcement is directed at and is only being distributed to: (A) persons in member states of the European Economic Area who are "qualified investors", as defined in article 2.1(e) of the Prospective Directive (Directive 2003/71/EC) as amended, (B) if in the United Kingdom, persons who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "FPO") or fall within the definition of "high net worth companies, unincorporated associations etc" in article 49(2)(a) to (d) of the FPO and (ii) are "qualified investors" as defined in section 86 of FSMA or (C) persons to whom it may otherwise lawfully be communicated (each, a "Relevant Person"). No other person should act or rely on this announcement and persons distributing this announcement must satisfy themselves that it is lawful to do so. By accepting the terms of this announcement, you represent and agree that you are a Relevant Person.

This announcement must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement or the Placing relate is available only to Relevant Persons and will be engaged in only with Relevant Persons. As regards all persons other than Relevant Persons, the details of the Placing set out in this announcement are for information purposes only.

Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this announcement should seek appropriate advice before taking any action.

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "could", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by the FCA, the London Stock Exchange, the AIM Rules or applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Any indication in this announcement of the price at which the Ordinary Shares have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

Shore Capital which is authorised and regulated in the United Kingdom by the FCA, are acting for the Company and for no one else in connection with the Placing and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Shore Capital or or for affording advice in relation to the Placing, or any other matters referred to in this announcement.

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by either Shore Capital or by any of their respective affiliates or either Shore Capital or their respective affiliates' agents, directors, officers and employees as to, or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed. Nothing in this Important notice shall be effective to limit or exclude any liability for fraud or which, by law or regulation, cannot otherwise be so limited or excluded.

The Placing Shares to be issued pursuant to the Placing will not be admitted to trading on any stock exchange other than AIM.

Members of the public are not eligible to take part in the Placing and no public offering of securities is or will be made.

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough biocontrol products and natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that it has agreed new terms covering its licence agreement with University of Massachusetts Medical School ("UMMS").

In Eden's 2016 Report and Accounts it was noted that an amount of £570,462, (USD$700,000) had been accrued to UMMS for minimum royalties payable under the licence agreement which Eden signed with UMMS in 2011. Eden has now agreed with UMMS to revise the minimum royalties from October 2017, resulting in a net reduction in Eden's short-term financial obligations to UMMS, with the amount accrued being written off in its entirety.

Eden has achieved this by signing an Amendment with UMMS, for which Eden has agreed to pay a fee of USD$250,000. A portion of this fee is payable upon signature of the Amendment, and the balance is payable in one year's time.

Sean Smith, Chief Executive of Eden, said: "We are pleased to announce the re-setting of some of the key commercial terms of our licence agreement with UMMS. We believe that the new terms reflect both the long term potential of our next-generation encapsulation technology whilst also reflecting the current stage of technology development. We look forward to the ongoing collaboration with UMMS which is, in part, focussed on the further development of this technology with the objective of creating a next-generation encapsulation system to help us solve a broader set of challenges for our partners."

This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy and France.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that its Annual Report and Accounts for the year ended 31 December 2016, Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders and are now available on the Company's website: www.edenresearch.com

The AGM is to be held on Friday 30 June 2017 at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED.

• 2016 Annual Report
• Notice of AGM to be held on 30 June 2017
• Proxy Form for 2017 AGM to be held on 30 June 2017

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus and Albania.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces its preliminary results for the year ended 31 December 2016.

Financial highlights

• Revenue of £0.4m (2015: £0.9m)
• Operating loss of £1.9m (2015: £1.1m)
• Operating loss, before non-cash share based payment charge and amortisation, of £1.1m (2015: £0.2m)
• Loss before tax of £1.9m (2015: £1.3m)
• Loss per share of 1.03p (2015: 0.74p)
• Net cash of £1.5m (2015: £0.15m)
• Equity accounting adopted in 2016 for Eden's investment in its associate, TerpeneTech, with prior period restated accordingly.
• Successful placing of £2.6m in March 2016

Operational highlights

• Lead agrochemical product 3AEY approvals granted for table and wine grape protection from botrytis in Spain, Italy and Bulgaria
• First commercial sales of lead agrochemical product, 3AEY, in Greece, Spain and Italy
• Exclusive commercialisation agreement with Eastman Chemical signed for Eden's nematicide product B2Y in nearly 30 countries representing a high percentage of the global nematicide demand
• 3AEY label extensions in Greece, Spain and Kenya for new crops and disease targets
• Appointment of Michel Villeneuve, as Senior Strategic Commercial Advisor, and Peter Watson, as Regulatory Strategy Advisor

Post Period end

• 3AEY approval granted in France for table and wine grape protection from botrytis
• First commercial scale order of 3AEY from SumiAgro in France
• Ongoing 3AEY sales in Kenya, Greece, Spain and Italy
• Extension of patent protection in Greece

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden’s encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden’s platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company’s technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden’s first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden’s technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden’s approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus and Albania.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

The following announcement has been released via RNS Reach, an investor communication service aimed at assisting listed and unlisted companies to distribute non-regulatory news releases such as marketing messages, corporate and product information into the public domain

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that yesterday's You & Yours, BBC Radio 4's consumer affairs programme, featured Eden Research plc's Mevalone, which used for the prevention and treatment of botrytis in table and wine grapes in a section of the programme labelled: The British innovation that's rejuvenating the French wine industry.

Shareholders can listen to the section from 23.45 until 30.14 here: 
http://www.bbc.co.uk/programmes/b08p5l79

Eden received approval for sale of Mevalone in France in January this year following extensive consideration by the French Authorities and Regulatory Agencies.

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy and France.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

Today's You & Yours programme on BBC Radio 4 featured Eden Research plc's Mevalone used for the prevention and treatment of botrytis in table and wine grapes: The British innovation that's rejuvenating the French wine industry.

Listen from 23.45 until 30.14 http://www.bbc.co.uk/programmes/b08p5l79

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that is has received a Supplementary Protection Certificate from the Patent Office in Greece for its 3AEY plant protection product.

A Supplementary Protection Certificate extends the duration of a patent in relation to a specific product. In Eden's case, this means a five-year extension to the patent protection for Eden's fungicide product, 3AEY, which has now been extended in Greece until May 2030. 3AEY is protected under Patent No. 3082101, entitled: "Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them."

Eden supplies 3AEY to its partner in Greece, K&N Efthymiadis, who then distributes the product (marketed as 'Mevalone') to its customers.  3AEY is also marketed in Italy as '3logy', in Spain as 'ARAW', in Kenya as 'Hawk' and will be sold in France from this year as 'Mevalone'.

Sean Smith, Chief Executive Officer of Eden, said: "Intellectual property is a critical element for Eden's success and value creation.  A five-year extension for the patent which covers our first product is valuable to both us and our partners.

"This is the first of several applications for Supplementary Protection Certificates in key territories.  As part of the Company's ongoing intellectual property lifecycle management, we are pursing the extension of patented rights in key markets globally."

Notes:

Eden Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.

In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy and France.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit: www.edenresearch.com

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, is today confirming its current total voting rights and number of  options and warrants outstanding.

The Company's total issued and voting share capital comprises 184,654,119 ordinary shares of 1 pence each ("Ordinary Shares"). No shares were held in treasury at the date of this announcement. The total number of current voting rights in the Company is therefore 184,654,119.

The above figure (184,654,119 Ordinary Shares) is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company.

The Company also confirms that the current number of outstanding warrants over Ordinary Shares ("Warrants") is currently 5,497,867, which is unchanged from the number of Warrants in issue announced by the Company on 27 September 2016. This number includes 2,000,000 Warrants with an exercise price of 11 pence which were issued to Oxford Capital Limited. These Warrants were issued in December 2014 in connection with the 20,865,382 new Ordinary Shares issued, as announced by the Company on 28 November 2014, for settlement of all outstanding debt.

In addition, the Company confirms that the current number of outstanding options over Ordinary Shares is currently 5,025,000.